XELJANZ XR is a Oral Tablet, Extended Release in the Human Prescription Drug category. It is labeled and distributed by U.s. Pharmaceuticals. The primary component is Tofacitinib Citrate.
| Product ID | 63539-501_11ae0c37-f8b9-44bf-b4a7-aef76dd348e3 |
| NDC | 63539-501 |
| Product Type | Human Prescription Drug |
| Proprietary Name | XELJANZ XR |
| Generic Name | Tofacitinib |
| Dosage Form | Tablet, Extended Release |
| Route of Administration | ORAL |
| Marketing Start Date | 2016-03-07 |
| Marketing Category | NDA / NDA |
| Application Number | NDA208246 |
| Labeler Name | U.S. Pharmaceuticals |
| Substance Name | TOFACITINIB CITRATE |
| Active Ingredient Strength | 11 mg/1 |
| Pharm Classes | Janus Kinase Inhibitor [EPC],Janus Kinase Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2016-03-07 |
| NDC Exclude Flag | N |
| Sample Package? | Y |
| Marketing Category | NDA |
| Application Number | NDA208246 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2016-03-07 |
| Marketing Category | NDA |
| Application Number | NDA208246 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2016-03-07 |
| Ingredient | Strength |
|---|---|
| TOFACITINIB CITRATE | 11 mg/1 |
| SPL SET ID: | 68e3d6b2-7838-4d2d-a417-09d919b43e13 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 63539-501 | XELJANZ XR | XELJANZ XR |
| 63539-502 | XELJANZ XR | XELJANZ XR |
| 0069-0501 | XELJANZ | tofacitinib |
| 0069-0502 | XELJANZ | tofacitinib |
| 0069-1001 | XELJANZ | tofacitinib |
| 0069-1002 | XELJANZ | tofacitinib |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() XELJANZ 86126490 4563705 Live/Registered |
Pfizer Inc. 2013-11-22 |
![]() XELJANZ 85678862 not registered Dead/Abandoned |
Pfizer Inc. 2012-07-17 |
![]() XELJANZ 77688128 4099367 Live/Registered |
Pfizer Inc. 2009-03-11 |